FDA clears Hologic's Localizer for long-term placement

By AuntMinnie.com staff writers

January 18, 2019 -- The U.S. Food and Drug Administration (FDA) has cleared women's imaging firm Hologic's Localizer radiofrequency identification (RFID) breast lesion localization device for long-term placement.

Localizer consists of an implantable tag that can be detected by a portable, handheld reader that indicates the location and distance to the lesion, the company said. The clearance allows the device to be implanted more than 30 days prior to breast-conserving surgery.

If you like this content, please share it with a colleague!

To read this and get access to all of the exclusive content on AuntMinnie.com create a free account or sign-in now.

Member Sign In:

MemberID or Email Address:

Do you have a AuntMinnie.com password?

No, I want a free membership.

Yes, I have a password:

Forgot your password?

View our privacy policy.